Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

Panelists discuss how:
HER2-low metastatic breast cancer represents a rapidly advancing treatment area, with novel ADCsantibody-drug conjugates driving paradigm shifts. The conversation centers on how these agents—by leveraging potent payload delivery—offer survival benefits previously unseen in this population. They examine HER3-directed therapies as an emerging frontier, considering their mechanistic rationale and early clinical trial outcomes. The experts discuss the expanding biomarker continuum that is blurring traditional HER2 categories and enabling personalized therapy strategies.